In this issue:
Patient experiences on the diagnosis, management, and burden of GPP
Baseline screening/monitoring with biologics for psoriasis
Impact of biologics on the development of PsA
A Japanese severity assessment tool for GPP
Cardiovascular risk in psoriasis and atopic dermatitis
Risankizumab clears high-impact sites in patients with psoriasis
“Treatment holidays” vs continuous maintenance with IL inhibitors in psoriasis
Biologic dose spacing in psoriasis
Paradoxical reactions to biologics in psoriasis
Managing psoriasis and atopic dermatitis and women’s reproductive health
Please login below to download this issue (PDF)